Bacteraemia incidence, causative organisms and resistance patterns, antibiotic strategies and outcomes in a single university hospital ICU: Continuing improvement between 2000 and 2013

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 1, 2015, Pages 273-278

  de santis, Vincenzo ^a   Gresoiu, Mihaela ^a   Corona, Alberto ^b   Wilson, A Peter R ^c   Singer, Mervyn ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Antibiotic combination therapy; Antibiotic duration; Antibiotic monotherapy; Antibiotic resistance; Fungaemia; Intensive care; Mortality

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CANDIDEMIA; FEMALE; FUNGEMIA; GRAM NEGATIVE SEPSIS; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATHOGENESIS; RELAPSE; RETROSPECTIVE STUDY; TREATMENT DURATION; UNIVERSITY HOSPITAL; BACTERIUM; CLASSIFICATION; DRUG EFFECTS; DRUG THERAPY; DRUG UTILIZATION; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIA; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY; DRUG UTILIZATION; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; LONDON; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84928343896     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku338     Document Type: Article

References (28)

1. Vincent JL, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-9.
2. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271: 1598-601.
3. Brun-Buisson C, Doyon F, Carlet J. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. Am J Respir Crit Care Med 1996; 154: 617-24.
4. Hugonnet S, Harbarth S, Ferrière K et al. Bacteremic sepsis in intensive care: temporal trends in incidence, organ dysfunction, and prognosis. Crit Care Med 2003; 31: 390-4.
5. Renaud B, Brun-Buisson C. Outcomes of primary and catheter-related bacteremia a cohort and case-control study in critically ill patients. Am J Respir Crit Care Med 2001; 163: 1584-90.
6. Vallés J, Palomar M, Alvárez-Lerma F et al. Evolution over a 15-year period of clinical characteristics and outcomes of critically ill patients with community-acquired bacteremia. Crit Care Med 2013; 41: 76-83.
7. Hecker MT, Aron DC, Patel NP et al. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the anti-anaerobic spectrum of activity. Arch Intern Med 2003; 163: 972-8.
8. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-77.
9. Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis 2011; 52: 1232-40.
10. Lambert M-L, Suetens C, Savey A et al. Clinical outcomes of healthcare-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis 2010; 11: 30-8.
11. Prowle JR, Heenen S, Singer M. Infection in the critically ill-questions we should be asking. J Antimicrob Chemother 2011; 66 Suppl 2: ii3-10.
12. Corona A, Wilson AP, Grassi M et al. Prospective audit of bacteraemia management in a university hospital ICU using a general strategy of shortcourse monotherapy. J Antimicrob Chemother 2004; 54: 809-17.
13. Davies SC, Fowler T, Watson J et al. Annual Report of the Chief Medical Officer: infection and the rise of antimicrobial resistance. Lancet 2013; 381: 1606-9.
14. PHE. Quarterly Epidemiological Commentary: Mandatory MRSA, MSSA and E. coli Bacteraemia, and C. difficile Infection Data (up to April-June 2013). London: PHE, September 2013. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317140446748.
15. Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care 2011; 15: R267.
16. Daneman N, Shore K, Pinto R et al. Antibiotic treatment duration for bloodstream infections in critically ill patients: a national survey of Canadian infectious diseases and critical care specialists. Int J Antimicrob Agents 2011; 38: 480-5.
17. Kett DH, Cano E, Quartin AA et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 2011; 11: 181-9.
18. Hranjec T, Rosenberger LH, Swenson B et al. Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study. Lancet Infect Dis 2012; 12: 774-80.
19. Jensen JU, Hein L, Lundgren B et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011; 39: 2048-58.
20. Corona A, Bertolini G, Lipman J et al. Antibiotic use and impact on outcome from bacteraemic critical illness: the Bacteraemia Study in Intensive Care (BASIC). J Antimicrob Chemother 2010; 65: 1276-85.
21. Corona A, Bertolini G, Ricotta AM et al. Variability of treatment duration for bacteraemia in the critically ill: a multinational survey. J Antimicrob Chemother 2003; 52: 849-52.
22. Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40: 32-40.
23. Hanberger H, Walther S, Leone M et al. Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. Int J Antimicrob Agents 2011; 38: 331-5.
24. de Kraker ME, Wolkewitz M, Davey PG et al. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 2011; 55: 1598-605.
25. van Duijn PJ, Dautzenberg MJD, Oostdijk EAN. Recent trends in antibiotic resistance in European ICUs. Curr Opin Crit Care 2011; 17: 658-65.
26. Bertrand X, Dowzicky MJ. Antimicrobial susceptibility among Gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial. Clin Ther 2012; 34: 124-37.
27. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
28. Ben-Ami R, Olshtain-Pops K, KriegerMet al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother 2012; 56: 2518-23.